News | April 22, 2013

IRadimed Corp. and HealthTrust Contract for MRidium MRI Infusion Pump System

Agreement makes MRidium systems available to HealthTrust members

MRidium 3860

April 22, 2013 — HealthTrust has awarded IRadimed Corp. a contract for its MRidium magnet resonance imaging (MRI) Infusion Pump Systems. The agreement makes the MRidium systems available to the more than 1,400 nonprofit and for-profit acute care facility members served by HealthTrust. The MRidium System was awarded the contract under HealthTrust's MR Compatible IV Pump category.

IRadimed's MRidium infusion pump is the only non-magnetic MRI IV pump solution currently available on the market today and is built from the ground up to deliver accurately and safely in the MRI area.

The MRidium 3860 MRI Infusion System offers optional integrated Masimo SET SpO2 capability for continuous monitoring of patients from the intensive care unit (ICU), neonatal intensive care unit (NICU,) neurology and other areas of the hospital right into the MRI suite. The 3860 System also offers an expanded drug library with Dose Error Reduction System (DERS), which helps prevent medication entry errors while programming infusions and provides the patient safety features that are quickly becoming the standard in infusion therapy in general patient care areas.

The MRidium System offers a modular second channel, which when attached to the 3860 IV Pump, allows for delivery of two medications simultaneously during patient scans. An optional wireless remote control monitor has true plug and play capabilities, requiring no installation. A full range of available infusion sets are also available to provide the clinical flexibility needed in the demanding MRI environment.

For more information:,

Related Content

Siemens Healthineers Launches New Partners for Digital Ecosystem at HIMSS 2018
News | PACS Accessories | March 12, 2018
At the 2018 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition, March 5-9...
Alternative Technique Can Improve Brain Imaging for Restless Children
News | Pediatric Imaging | March 08, 2018
March 8, 2018 – Children often find it difficult to remain still for...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
Imaging Plays Key Role in Evaluating Injuries at Olympics
News | Orthopedic Imaging | February 28, 2018
The Olympic Games give elite athletes a chance at athletic triumph, but also carry a risk of injury. When injuries...
FDA Clears Siemens Healthineers' GOKnee3D MRI Application
Technology | Magnetic Resonance Imaging (MRI) | February 19, 2018
The U.S. Food and Drug Administration (FDA) has cleared GOKnee3D, a magnetic resonance imaging (MRI) application from...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Arterys Receives First FDA Clearance for Oncology Imaging Suite With Deep Learning
Technology | Artificial Intelligence | February 15, 2018
Arterys Inc. announced its fifth 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Arterys...
Overlay Init